United States

Manojna Maddipatla

UPDATE 3-Supernus Pharma's ADHD treatment fails to impress; shares fall

Dec 06 2018

Dec 6 Supernus Pharmaceuticals Inc's treatment for attention deficit hyperactivity disorder met the main goal of two trials, but shares fell about 16 percent on Thursday as the data failed to convince some investors that the drug was better than rivals.

Revance Therapeutics' Botox rival succeeds in late-stage trial

Dec 04 2018

A potential rival for Allergan Plc's blockbuster Botox has passed a late-stage study, putting drug developer Revance Therapeutics Inc on course to file for U.S. marketing approval next year.

Pfizer-Lilly non-opioid drug helps reduce osteoarthritis pain

Oct 23 2018

A non-opioid drug developed by Pfizer and Eli Lilly met the main goals of a late-stage study, in which over half of the patients reported a significant reduction in osteoarthritis pain of the knee or hip.

Early approval of Alnylam's gene-silencing drug in question

Sep 27 2018

Alnylam Pharmaceuticals Inc said on Thursday it might have to hold off on plans to seek an accelerated approval for its gene-silencing drug, which showed effectiveness in a late-stage trial based on early data.

World News